



Role of Medicinal Plants in Novel Anticancer Drug Discovery: Phytochemical Diversity, Molecular Targets, and Translational Therapeutic Development

Dr. Jonathan Michael Harrington^{1*}, Emily Rose Whitaker², Dr. Christopher Alan Montgomery³

¹ PhD, Department of Pharmaceutical Nanotechnology, Center for Precision Oncology Therapeutics, Johns Hopkins University School of Pharmacy, Baltimore, USA.

² Division of Nanomedicine and Targeted Drug Delivery, University of California San Diego, USA.

³ Institute for Translational Cancer Nanotherapeutics, MD Anderson Cancer Center, Houston, USA.

* Corresponding Author: **Dr. Jonathan Michael Harrington**

Article Info

ISSN (online): 3107-393X

Volume: 01

Issue: 01

January – February 2024

Received: 05-11-2023

Accepted: 07-12-2023

Published: 09-01-2024

Page No: 16-23

Abstract

Medicinal plants represent an invaluable repository of structurally diverse bioactive compounds that have historically contributed to the development of clinically effective anticancer therapeutics. Over 60% of currently approved oncologic agents are derived from or inspired by natural products, underscoring the critical role of phytochemicals in cancer drug discovery pipelines. This review examines the contemporary landscape of plant-derived anticancer agents, focusing on their phytochemical diversity, molecular targets, and translational development pathways. We discuss major classes of bioactive compounds including alkaloids, terpenoids, polyphenols, and glycosides, highlighting their mechanisms of action across multiple hallmarks of cancer such as apoptosis induction, cell cycle arrest, angiogenesis inhibition, and metastasis suppression. Emphasis is placed on molecular targets and signaling pathways modulated by these compounds, including PI3K/Akt, MAPK, NF- κ B, and Wnt/ β -catenin cascades. The review explores modern drug discovery approaches including high-throughput screening, structure-activity relationship studies, and semi-synthetic modifications that enhance therapeutic efficacy and pharmacokinetic properties. Clinical translation of plant-derived compounds faces significant challenges including compound isolation complexity, limited bioavailability, and regulatory requirements. Nonetheless, successful examples such as paclitaxel, vincristine, and camptothecin derivatives demonstrate the transformative potential of medicinal plants in oncology. Future perspectives encompass computational drug design, nanotechnology-based delivery systems, and combination therapeutic strategies that may overcome current translational barriers and expand the anticancer arsenal derived from botanical sources.

DOI:

Keywords: Medicinal plants; Anticancer drug discovery; Phytochemicals; Molecular targets; Translational oncology; Natural product pharmacology

1. Introduction

Cancer remains one of the leading causes of mortality worldwide, with an estimated 19.3 million new cases and nearly 10 million deaths reported globally in 2020^[1]. Despite significant advances in molecular oncology and targeted therapeutics, the development of novel anticancer agents with improved efficacy, reduced toxicity, and capability to overcome drug resistance represents a paramount challenge in contemporary pharmaceutical research^[2]. Medicinal plants have served as essential sources of therapeutic compounds throughout human history, and their contribution to modern cancer pharmacotherapy is particularly

noteworthy [3]. Natural products and their derivatives constitute approximately 60% of all clinically approved anticancer drugs, demonstrating the unparalleled chemical diversity and biological activity inherent in plant-derived compounds [4]. Classical examples include the microtubule-targeting agents paclitaxel from *Taxus brevifolia* and the vinca alkaloids from *Catharanthus roseus*, topoisomerase inhibitors derived from camptothecin isolated from *Camptotheca acuminata*, and podophyllotoxin derivatives from *Podophyllum* species [5, 6]. These compounds exhibit complex molecular architectures that would be challenging to synthesize through conventional medicinal chemistry approaches, representing privileged scaffolds optimized through millions of years of evolutionary selection [7].

The rationale for investigating medicinal plants as sources of anticancer leads extends beyond historical precedent. Phytochemicals demonstrate remarkable structural diversity, encompassing alkaloids, terpenoids, polyphenols, flavonoids, saponins, and other compound classes that interact with multiple molecular targets implicated in oncogenesis [8]. Modern understanding of cancer biology emphasizes the importance of targeting multiple hallmarks of cancer simultaneously, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, invasion, and metastasis [9]. Plant-derived compounds frequently exhibit poly pharmacological properties, modulating multiple pathways and targets that collectively contribute to their anticancer efficacy [10].

This review provides a comprehensive examination of medicinal plants in the context of contemporary anticancer drug discovery, emphasizing phytochemical diversity, molecular mechanisms of action, translational development strategies, and the challenges inherent in advancing botanical leads from laboratory investigation to clinical application. By focusing on mechanistic insights and drug development paradigms, we aim to provide a framework for understanding how medicinal plants continue to shape the landscape of cancer therapeutics.

2. Medicinal Plants as Sources of Anticancer Agents

The chemical diversity present in medicinal plants offers a vast library of molecular scaffolds with potential anticancer activity. Unlike synthetic compound libraries that are constrained by established chemical space, plant metabolites represent evolutionarily refined structures that occupy unique regions of chemical diversity space [11]. This diversity arises from the secondary metabolism of plants, where biosynthetic pathways generate complex molecules serving ecological functions such as defense against pathogens, herbivores, and environmental stressors [12].

Several plant families have proven particularly prolific as sources of anticancer compounds. The Apocynaceae family has yielded the clinically essential vinca alkaloids vincristine and vinblastine, which disrupt microtubule dynamics and remain frontline therapies for hematological malignancies and solid tumors [13]. Taxanes, including paclitaxel and docetaxel, derived from *Taxus* species (Taxaceae), represent another cornerstone of cancer chemotherapy, functioning as microtubule stabilizers with broad-spectrum activity across multiple cancer types [14]. The Berberidaceae family has contributed podophyllotoxin, the precursor to the semisynthetic topoisomerase II inhibitors etoposide and teniposide [15].

Beyond these established therapeutic agents, numerous medicinal plants are under intensive investigation as sources of novel anticancer leads. *Curcuma longa* (Zingiberaceae) produces curcumin, a polyphenolic compound demonstrating pleiotropic anticancer effects through modulation of multiple signaling pathways [16]. *Camellia sinensis* (Theaceae) contains epigallocatechin gallate (EGCG), a flavonoid with demonstrated anti-proliferative, pro-apoptotic, and anti-angiogenic properties [17]. Resveratrol from *Vitis vinifera* and various berries exhibits anticancer activity through SIRT1 activation and modulation of metabolic pathways [18].

The Combretaceae family has attracted attention for combretastatins isolated from *Combretum caffrum*, which function as vascular disrupting agents targeting tumor vasculature [19]. Betulinic acid from *Betula* species demonstrates selective cytotoxicity against melanoma cells through mitochondrial pathway activation [20]. Compounds from *Artemisia annua*, traditionally used for malaria treatment, have shown promising anticancer activity, particularly artesunate's ability to generate reactive oxygen species and induce ferroptosis in cancer cells [21].

The systematic investigation of medicinal plants for anticancer compounds involves ethnobotanical knowledge, bioassay-guided fractionation, and advanced analytical techniques. High-throughput screening platforms enable rapid evaluation of plant extracts and purified compounds against cancer cell panels, while metabolomics approaches facilitate comprehensive chemical profiling [22]. This integration of traditional knowledge with modern technology accelerates the identification of bioactive compounds and their development as therapeutic leads.

3. Bioactive Phytochemicals and Molecular Mechanisms

Plant-derived anticancer compounds encompass diverse chemical classes, each exhibiting distinct molecular mechanisms that target fundamental processes underlying cancer progression. Understanding these mechanisms at the molecular level is essential for rational drug development and identification of potential combination therapies.

3.1. Alkaloids

Alkaloids represent nitrogen-containing compounds with potent biological activities and established clinical utility in oncology. Vinca alkaloids bind to tubulin at the vinca domain, preventing microtubule polymerization and causing mitotic arrest in metaphase [23]. This disruption of the mitotic spindle activates the spindle assembly checkpoint, ultimately triggering apoptosis through both intrinsic and extrinsic pathways [24]. Camptothecin and its derivatives (topotecan, irinotecan) stabilize the topoisomerase I-DNA cleavage complex, preventing DNA relegation and generating DNA strand breaks that activate p53-dependent apoptotic responses [25].

Berberine, an isoquinoline alkaloid, demonstrates anticancer effects through multiple mechanisms including cell cycle arrest at G1 phase via downregulation of cyclin D1 and CDK4, induction of apoptosis through mitochondrial dysfunction, and inhibition of metastasis by suppressing matrix metalloproteinase expression [26]. Sanguinarine induces apoptosis through generation of reactive oxygen species, mitochondrial membrane potential disruption, and activation of caspase cascades [27].

3.2. Terpenoids

Terpenoids constitute the largest class of natural products, with several demonstrating significant anticancer potential. Paclitaxel stabilizes microtubules by binding to β -tubulin, preventing depolymerization and causing cell cycle arrest in G2/M phase^[28]. Beyond microtubule stabilization, paclitaxel activates multiple stress-response pathways including c-Jun N-terminal kinase (JNK) and p38 MAPK, contributing to its cytotoxic effects^[29].

Betulinic acid selectively induces apoptosis in cancer cells through direct effects on mitochondria, causing mitochondrial membrane permeabilization independent of death receptors or Bcl-2 family regulation^[30]. This compound also inhibits topoisomerase I and activates AMPK, disrupting energy metabolism in cancer cells^[31]. Artemisinin derivatives generate carbon-centered radicals through iron-catalyzed cleavage of their endoperoxide bridge, causing oxidative damage to proteins and DNA while inducing ferroptosis through glutathione depletion^[32].

3.3. Polyphenols and Flavonoids

Polyphenolic compounds exhibit anticancer effects through antioxidant activity, modulation of signaling pathways, and epigenetic regulation. Curcumin inhibits NF- κ B activation by preventing I κ B kinase activity, thereby suppressing expression of pro-survival genes including Bcl-2, cyclin D1, and matrix metalloproteinases^[33]. Additionally, curcumin modulates the PI3K/Akt/mTOR pathway, MAPK signaling, and JAK/STAT pathways, demonstrating remarkable polypharmacology^[34].

EGCG inhibits receptor tyrosine kinases including EGFR and HER2, blocking downstream activation of PI3K/Akt and MAPK pathways^[35]. This flavonoid also modulates DNA methyltransferases and histone deacetylases, resulting in epigenetic reactivation of tumor suppressor genes^[36]. Resveratrol activates SIRT1, promoting deacetylation of p53 and enhancing its transcriptional activity while also inhibiting COX-2 and reducing prostaglandin synthesis^[37].

3.4. Targeting Hallmarks of Cancer

Plant-derived compounds effectively target multiple hallmarks of cancer. Apoptosis induction occurs through both intrinsic (mitochondrial) and extrinsic (death receptor) pathways. Compounds such as camptothecin, betulinic acid, and sanguinarine induce mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation^[38]. Cell cycle arrest is mediated through modulation of cyclin-dependent kinases and their inhibitors, with many phytochemicals inducing G1, S, or G2/M phase arrest depending on their molecular targets^[39].

Angiogenesis inhibition represents another crucial mechanism, with compounds like combretastatins disrupting tumor vasculature and EGCG suppressing VEGF expression and signaling^[40]. Metastasis suppression occurs through inhibition of epithelial-mesenchymal transition, downregulation of matrix metalloproteinases, and disruption of integrin-mediated cell adhesion^[41]. Several phytochemicals also demonstrate immunomodulatory properties, enhancing natural killer cell activity and promoting antitumor immune responses^[42].

4. Modern Approaches in Anticancer Drug Discovery from Plants

Contemporary anticancer drug discovery from medicinal plants integrates traditional knowledge with cutting-edge technologies and rational drug design principles. This multidisciplinary approach accelerates lead identification, optimization, and translational development.

4.1. High-Throughput Screening and Bioassay-Guided Fractionation

High-throughput screening (HTS) platforms enable rapid evaluation of plant extracts and compound libraries against cancer cell lines, primary patient-derived cells, and molecular targets^[43]. Automated systems can screen thousands of samples, identifying hits based on cytotoxicity, target inhibition, or phenotypic changes. Bioassay-guided fractionation systematically isolates bioactive compounds through iterative extraction, chromatographic separation, and biological testing^[44]. This approach, combined with advanced analytical techniques including liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance (NMR) spectroscopy, enables rapid structure elucidation of active constituents.

4.2. Structure-Activity Relationship Studies

Understanding structure-activity relationships (SAR) is fundamental to optimizing phytochemical leads. Systematic modification of chemical scaffolds reveals functional groups essential for biological activity and identifies positions amenable to derivatization^[45]. Semi-synthetic modification of natural products has yielded clinically superior agents; docetaxel represents a semi-synthetic taxane with improved pharmacokinetic properties and water solubility compared to paclitaxel^[46]. Similarly, topotecan and irinotecan are camptothecin derivatives with enhanced stability and therapeutic index^[47].

4.3. Target Identification and Validation

Modern chemical biology approaches facilitate target identification for bioactive phytochemicals. Affinity-based proteomics, using immobilized compounds as baits, enables unbiased identification of protein targets^[48]. Chemical genetics, employing systematic genetic or pharmacological perturbation, validates target engagement and pathway dependencies^[49]. CRISPR-Cas9 screening complements these approaches, identifying genes whose loss sensitizes or confers resistance to specific compounds^[50].

4.4. Computational Drug Design

In silico approaches accelerate drug discovery by predicting compound-target interactions, optimizing pharmacokinetic properties, and designing improved derivatives. Molecular docking simulates binding of phytochemicals to target proteins, providing structural insights for rational modification. Pharmacophore modeling identifies essential features for biological activity, guiding library design and virtual screening. Quantitative structure-activity relationship (QSAR) models predict activity based on molecular descriptors, enabling prioritization of synthetic efforts.

4.5. Formulation and Delivery Systems

Many phytochemicals exhibit poor water solubility, limited bioavailability, and rapid metabolism, necessitating advanced formulation strategies. Nanoparticle-based delivery systems, including liposomes, polymeric nanoparticles, and solid lipid nanoparticles, enhance compound stability, tumor accumulation through enhanced permeability and retention effect, and controlled release. Albumin-bound paclitaxel (nab-paclitaxel) exemplifies successful reformulation, achieving higher intratumoral concentrations and improved therapeutic index compared to conventional formulations.

5. Therapeutic and Clinical Applications

The clinical success of plant-derived anticancer agents validates medicinal plants as sources of transformative therapeutics. Several compounds have achieved regulatory approval and occupy essential positions in cancer treatment protocols.

5.1. Clinically Approved Plant-Derived Anticancer Drugs

Vinca alkaloids remain indispensable components of combination chemotherapy regimens. Vincristine is utilized in treating acute lymphoblastic leukemia, Hodgkin lymphoma, and neuroblastoma, while vinblastine is employed for Hodgkin lymphoma and testicular cancer. Taxanes, particularly paclitaxel and docetaxel, represent first-line or second-line therapies for breast, ovarian, lung, and prostate cancers. The topoisomerase inhibitors topotecan and irinotecan are approved for ovarian cancer and colorectal cancer, respectively.

Etoposide and teniposide, semi-synthetic podophyllotoxin derivatives, are used in treating small cell lung cancer, testicular cancer, and hematological malignancies. More recent additions include cabazitaxel, a next-generation taxane approved for metastatic castration-resistant prostate cancer. Trabectedin, derived from the marine tunicate *Ecteinascidia turbinata* (though originally of bacterial symbiont origin), demonstrates the broader applicability of natural product discovery principles to anticancer therapeutics.

5.2. Compounds in Clinical Development

Numerous plant-derived compounds are progressing through clinical trials. Combretastatin A-4 phosphate, a prodrug of the tubulin-binding vascular disrupting agent, has shown promising results in Phase II/III trials for anaplastic thyroid cancer and ovarian cancer. Homoharringtonine (omacetaxine mepesuccinate), isolated from *Cephalotaxus* species, received FDA approval for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.

Curcumin has entered numerous clinical trials, often in combination with conventional therapies, for pancreatic, colorectal, and breast cancers, though bioavailability limitations have necessitated novel formulation strategies. Silvestrol, a roscaglate compound from *Aglaia foveolata*, demonstrates potent inhibition of eIF4A and is advancing in preclinical development with promising activity against triple-negative breast cancer and acute myeloid leukemia.

5.3. Combination Therapies and Chemosensitization

Plant-derived compounds increasingly serve as chemosensitizers, overcoming drug resistance and enhancing efficacy of conventional therapeutics. Curcumin sensitizes cancer cells to chemotherapy and radiotherapy by inhibiting

NF- κ B-mediated survival signaling. Quercetin reverses multidrug resistance by inhibiting P-glycoprotein efflux pumps and modulating drug metabolism enzymes. Combination regimens integrating phytochemicals with targeted therapies or immunotherapies represent promising strategies for achieving synergistic anticancer effects while minimizing toxicity.

6. Challenges and Translational Barriers

Despite their therapeutic promise, plant-derived anticancer compounds face significant challenges in translational development that must be addressed to realize their full clinical potential.

6.1. Compound Isolation and Supply

Isolating sufficient quantities of bioactive compounds from plant sources presents practical and ethical challenges. Many anticancer phytochemicals occur in low concentrations, requiring extensive plant material and complex isolation procedures. Paclitaxel's initial development was hindered by limited supply from *Taxus brevifolia* bark, necessitating development of semi-synthetic production from renewable precursors and eventually total synthesis and cell culture approaches. Sustainable sourcing strategies, including plant cell culture, metabolic engineering, and synthetic biology, are essential for ensuring adequate compound supply while preserving biodiversity.

6.2. Bioavailability and Pharmacokinetics

Many phytochemicals exhibit poor oral bioavailability due to low water solubility, extensive first-pass metabolism, and efflux transporter activity. Curcumin, despite potent *in vitro* anticancer activity, demonstrates extremely low systemic bioavailability, limiting clinical efficacy. Strategies to enhance bioavailability include chemical modification to improve solubility, formulation in nanocarriers or lipid-based systems, and co-administration with bioavailability enhancers such as piperine.

6.3. Selectivity and Toxicity

Achieving selective cancer cell toxicity while sparing normal tissues remains a fundamental challenge. Microtubule-targeting agents such as vinca alkaloids and taxanes cause significant neurotoxicity due to effects on neuronal microtubules. Structure-activity relationship studies and rational modification can enhance selectivity, as exemplified by development of antibody-drug conjugates that deliver cytotoxic payloads specifically to tumor cells expressing target antigens.

6.4. Standardization and Quality Control

The complex composition of plant extracts necessitates rigorous standardization and quality control to ensure batch-to-batch consistency and reproducibility. Variation in phytochemical content due to genetic diversity, environmental factors, and processing methods can impact efficacy and safety. Analytical methods employing chromatographic fingerprinting, metabolomics profiling, and quantification of marker compounds are essential for quality assurance.

6.5. Regulatory Requirements

Advancing plant-derived compounds through regulatory approval requires extensive preclinical and clinical

investigation demonstrating safety, efficacy, and quality. Regulatory agencies require comprehensive data on pharmacology, toxicology, manufacturing, and clinical outcomes. The pathway from traditional use to approved medicine demands substantial investment and adherence to Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP) standards.

7. Future Perspectives

The future of anticancer drug discovery from medicinal plants will be shaped by technological advances, interdisciplinary collaboration, and innovative therapeutic paradigms.

7.1. Artificial Intelligence and Machine Learning

Artificial intelligence and machine learning algorithms are transforming natural product discovery by predicting bioactivity, optimizing lead compounds, and identifying novel targets. Deep learning models trained on chemical structure and biological activity data can prioritize compounds for synthesis and testing, accelerating hit identification. Integration of multi-omics data enables systems-level understanding of compound mechanisms and resistance pathways.

7.2. Synthetic Biology and Metabolic Engineering

Synthetic biology approaches enable sustainable production of complex phytochemicals in microbial hosts, eliminating dependence on plant harvesting. Reconstruction of biosynthetic pathways in engineered yeast or bacteria has successfully produced taxadiene (paclitaxel precursor), artemisinic acid, and other terpenoids at industrially relevant scales. CRISPR-based genome editing of plant hosts can enhance production of bioactive compounds or generate novel analogs through pathway engineering.

7.3. Precision Medicine and Biomarker-Driven Development

Biomarker stratification will enable identification of patient populations most likely to benefit from specific plant-derived therapeutics. Genomic, transcriptomic, and proteomic profiling can reveal vulnerabilities targetable by phytochemicals. For instance, cancers with defective DNA repair mechanisms may demonstrate enhanced sensitivity to topoisomerase inhibitors, while tumors dependent on specific

metabolic pathways may respond to compounds disrupting those processes.

7.4. Immunomodulatory Applications

Emerging evidence suggests certain phytochemicals enhance antitumor immunity through multiple mechanisms including modulation of immune checkpoints, enhancement of antigen presentation, and reprogramming of the tumor microenvironment [90]. Combination of immunomodulatory phytochemicals with checkpoint inhibitors or cellular immunotherapies represents an attractive strategy for improving response rates and overcoming resistance.

7.5. Overcoming Drug Resistance

Drug resistance remains a major impediment to cancer cure. Plant-derived compounds that reverse resistance mechanisms, including efflux pump inhibitors, epigenetic modulators, and compounds targeting cancer stem cells, offer promising strategies. Multi-targeted phytochemicals may prevent emergence of resistance by simultaneously attacking multiple vulnerabilities, while rational combinations can achieve synthetic lethality in resistant cell populations.

8. Conclusion

Medicinal plants represent an evolutionarily refined library of structurally diverse compounds with validated potential in cancer therapeutics. From established clinical agents such as taxanes and vinca alkaloids to emerging compounds in preclinical development, plant-derived anticancer agents demonstrate the continued relevance of natural products in modern drug discovery. Understanding molecular mechanisms, identifying relevant targets, and employing advanced technologies for lead optimization and formulation are essential for translating botanical leads into clinical therapeutics.

The challenges of compound isolation, bioavailability limitations, and regulatory requirements are increasingly addressable through synthetic biology, nanotechnology, and rational drug design. Future advances in artificial intelligence, precision medicine, and immunomodulation will further expand the therapeutic potential of plant-derived anticancer agents. By integrating traditional knowledge with contemporary pharmaceutical sciences, medicinal plants will continue to contribute transformative therapeutics to the anticancer arsenal, offering hope for improved patient outcomes in the global fight against cancer.

9. Tables

Table 1: Medicinal Plants and Their Bioactive Anticancer Phytochemicals

Plant Species	Family	Bioactive Compound(s)	Chemical Class	Primary Mechanism
<i>Catharanthus roseus</i>	Apocynaceae	Vincristine, Vinblastine	Alkaloids	Microtubule depolymerization
<i>Taxus brevifolia</i>	Taxaceae	Paclitaxel, Docetaxel	Terpenoids (taxanes)	Microtubule stabilization
<i>Camptotheca acuminata</i>	Nyssaceae	Camptothecin	Alkaloid	Topoisomerase I inhibition
<i>Podophyllum peltatum</i>	Berberidaceae	Podophyllotoxin	Lignan	Topoisomerase II inhibition
<i>Curcuma longa</i>	Zingiberaceae	Curcumin	Polyphenol	NF- κ B, PI3K/Akt modulation
<i>Camellia sinensis</i>	Theaceae	EGCG	Flavonoid	RTK inhibition, epigenetic modulation
<i>Combretum caffrum</i>	Combretaceae	Combretastatin A-4	Stilbenoid	Vascular disruption
<i>Betula</i> spp.	Betulaceae	Betulinic acid	Triterpenoid	Mitochondrial apoptosis
<i>Artemisia annua</i>	Asteraceae	Artesunate	Sesquiterpene lactone	ROS generation, ferroptosis
<i>Cephalotaxus</i> spp.	Taxaceae	Homoharringtonine	Alkaloid	Protein synthesis inhibition

Table 2: Molecular Targets and Mechanisms of Action of Plant-Derived Anticancer Agents

Compound	Primary Target(s)	Signaling Pathway(s) Affected	Cancer Hallmark(s) Targeted	Clinical Status
Vincristine	β -tubulin (vinca domain)	Mitotic spindle checkpoint	Sustained proliferation, cell death resistance	FDA approved
Paclitaxel	β -tubulin (taxane site)	MAPK, JNK activation	Sustained proliferation	FDA approved
Camptothecin derivatives	Topoisomerase I	DNA damage response, p53	Genome instability	FDA approved
Etoposide	Topoisomerase II	DNA damage, apoptosis	Genome instability	FDA approved
Curcumin	I κ B kinase, multiple RTKs	NF- κ B, PI3K/Akt, MAPK, JAK/STAT	Inflammation, cell death resistance	Clinical trials
EGCG	EGFR, HER2, DNMTs, HDACs	PI3K/Akt, MAPK, epigenetic	Proliferation, epigenetics	Clinical trials
Combretastatin A-4	Tubulin, vascular endothelium	Vascular disruption	Angiogenesis	Clinical trials
Betulinic acid	Mitochondria, topoisomerase I	Intrinsic apoptosis, AMPK	Cell death resistance, metabolism	Preclinical
Resveratrol	SIRT1, COX-2	Metabolic regulation, inflammation	Inflammation, metabolism	Clinical trials
Artesunate	Iron-mediated ROS	Oxidative stress, ferroptosis	Redox homeostasis	Preclinical/Clinical trials

Table 3: Advantages, Limitations, and Translational Challenges in Plant-Based Anticancer Drug Discovery

Aspect	Advantages	Limitations	Translational Strategies
Chemical Diversity	<ul style="list-style-type: none"> Unique chemical scaffolds Evolutionarily optimized structures Access to unexplored chemical space 	<ul style="list-style-type: none"> Structural complexity Difficult total synthesis Limited chemical modification 	<ul style="list-style-type: none"> Semi-synthetic approaches Biosynthetic pathway engineering Fragment-based drug design
Multi-targeting	<ul style="list-style-type: none"> Polypharmacological effects Modulation of multiple pathways Potential synergy 	<ul style="list-style-type: none"> Complex mechanism elucidation Difficult target validation Unpredictable interactions 	<ul style="list-style-type: none"> Systems pharmacology Proteomics profiling Network analysis
Supply and Sourcing	<ul style="list-style-type: none"> Renewable resource Biodiversity reservoir 	<ul style="list-style-type: none"> Limited availability Seasonal variation Environmental impact Biodiversity concerns 	<ul style="list-style-type: none"> Plant cell culture Microbial production Synthetic biology Total synthesis
Bioavailability	<ul style="list-style-type: none"> Natural bioactivity 	<ul style="list-style-type: none"> Poor water solubility Extensive metabolism Low oral absorption Efflux susceptibility 	<ul style="list-style-type: none"> Nanoformulations Prodrug design Chemical modification Absorption enhancers
Selectivity	<ul style="list-style-type: none"> Selective cancer cytotoxicity (some compounds) 	<ul style="list-style-type: none"> Off-target effects Normal tissue toxicity 	<ul style="list-style-type: none"> Structure optimization Targeted delivery Antibody-drug conjugates
Development Timeline	<ul style="list-style-type: none"> Known biological activity Traditional use evidence 	<ul style="list-style-type: none"> Complex isolation Extensive characterization Regulatory requirements 	<ul style="list-style-type: none"> Bioassay-guided fractionation Advanced analytics Regulatory science collaboration

10. Figures


**Fig 1:** Workflow of Anticancer Drug Discovery from Medicinal Plants

Figure 1. Systematic workflow depicting the translational pipeline for anticancer drug discovery from medicinal plants. The process integrates traditional knowledge, modern

analytical techniques, and pharmaceutical development strategies to advance bioactive phytochemicals from plant sources to clinical therapeutics.




Fig 2: Molecular Mechanisms and Signaling Pathways Targeted by Plant-Derived Anticancer Compounds

Figure 2. Comprehensive illustration of molecular mechanisms and signaling pathways targeted by plant-derived anticancer compounds. The diagram depicts major oncogenic pathways including receptor tyrosine kinase signaling (PI3K/Akt, MAPK), inflammatory signaling (NF- κ B), apoptosis regulation (intrinsic and extrinsic pathways), cell cycle control, angiogenesis, and nuclear events (DNA damage, epigenetic modulation). Representative phytochemicals are indicated at their sites of action, demonstrating the multi-targeted nature of plant-derived anticancer agents.

References

- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49.
- Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. *Adv Pharm Bull.* 2017;7(3):339-48.
- Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *J Nat Prod.* 2020;83(3):770-803.
- Atanasov AG, Zotchev SB, Dirsch VM, Supuran CT. Natural products in drug discovery: advances and opportunities. *Nat Rev Drug Discov.* 2021;20(3):200-16.
- Weaver BA. How Taxol/paclitaxel kills cancer cells. *Mol Biol Cell.* 2014;25(18):2677-81.
- Moudi M, Go R, Yien CY, Nazre M. Vinca alkaloids. *Int J Prev Med.* 2013;4(11):1231-5.
- Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. *Nat Chem.* 2016;8(6):531-41.
- Cragg GM, Pezzuto JM. Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. *Med Princ Pract.* 2016;25(Suppl 2):41-59.
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* 2011;144(5):646-74.
- Zhou J, Jiang X, He S, Jiang H, Feng F, Liu W, *et al.* Rational design of multitarget-directed ligands: strategies and emerging paradigms. *J Med Chem.* 2019;62(20):8881-914.
- Chen Y, de Bruyn Kops C, Kirchmair J. Data resources for the computer-guided discovery of bioactive natural products. *J Chem Inf Model.* 2017;57(9):2099-111.
- Wink M. Modes of action of herbal medicines and plant secondary metabolites. *Medicines (Basel).* 2015;2(3):251-86.
- Mohan R, Hammers HJ, Bargagna-Mohan P, Zhan XH, Herbstritt CJ, Ruiz A, *et al.* Withaferin A is a potent inhibitor of angiogenesis. *Angiogenesis.* 2004;7(2):115-22.
- Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T. A comprehensive review about Taxol: history and future challenges. *Molecules.* 2020;25(24):5986.
- Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. *Eur J Cancer.* 1998;34(10):1514-21.
- Giordano A, Tommonaro G. Curcumin and cancer. *Nutrients.* 2019;11(10):2376.
- Yang CS, Wang H, Li GX, Yang Z, Guan F, Jin H. Cancer prevention by tea: evidence from laboratory studies. *Pharmacol Res.* 2011;64(2):113-22.
- Varoni EM, Lo Faro AF, Sharifi-Rad J, Iriti M. Anticancer molecular mechanisms of resveratrol. *Front Nutr.* 2016;3:8.

19. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). *Expert Opin Investig Drugs*. 2009;18(2):189-97.
20. Fulda S. Targeting mitochondrial apoptosis by betulinic acid in human cancers. *Drug Discov Today*. 2009;14(17-18):885-90.
21. Efferth T. From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy. *Semin Cancer Biol*. 2017;46:65-83.
22. Atanasov AG, Waltenberger B, Pferschy-Wenzig EM, Linder T, Wawrosch C, Uhrin P, *et al*. Discovery and resupply of pharmacologically active plant-derived natural products: a review. *Biotechnol Adv*. 2015;33(8):1582-614.
23. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. *Nat Rev Cancer*. 2004;4(4):253-65.
24. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. *Apoptosis*. 2003;8(5):413-50.
25. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer*. 2006;6(10):789-802.
26. Sun Y, Xun K, Wang Y, Chen X. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. *Anticancer Drugs*. 2009;20(9):757-69.
27. Chaturvedi MM, Kumar A, Darnay BG, Chainy GB, Agarwal S, Aggarwal BB. Sanguinarine (pseudochelethrythrine) is a potent inhibitor of NF-kappaB activation, IkappaBalpha phosphorylation, and degradation. *J Biol Chem*. 1997;272(48):30129-34.
28. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. *Nature*. 1979;277(5698):665-7.
29. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. *Cancer*. 2000;88(11):2619-28.
30. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME, *et al*. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. *J Biol Chem*. 1998;273(51):33942-8.
31. Chintharlapalli S, Papineni S, Ramaiah SK, Safe S. Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors. *Cancer Res*. 2007;67(6):2816-23.
32. Eling N, Reuter L, Hazin J, Hamacher-Brady A, Brady NR. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. *Oncoscience*. 2015;2(5):517-32.
33. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. *Trends Pharmacol Sci*. 2009;30(2):85-94.
34. Giordano A, Tommonaro G. Curcumin and cancer. *Nutrients*. 2019;11(10):2376.
35. Shimizu M, Fukutomi Y, Ninomiya M, Nagura K, Kato T, Araki H, *et al*. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. *Cancer Epidemiol Biomarkers Prev*. 2008;17(11):3020-5.
36. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, *et al*. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. *Cancer Res*. 2003;63(22):7563-70.
37. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. *Cancer Lett*. 2008;269(2):243-61.
38. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. *J Exp Clin Cancer Res*. 2011;30(1):87.
39. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. *Nature*. 2001;411(6835):342-8.
40. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med*. 1995;1(1):27-31.
41. Gupta GP, Massagué J. Cancer metastasis: building a framework. *Cell*. 2006;127(4):679-95.
42. Bishayee A, Sethi G. Bioactive natural products in cancer prevention and therapy: progress and promise. *Semin Cancer Biol*. 2016;40-41:1-3.
43. Pereira DM, Valentão P, Andrade PB. Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones. *Chem Sci*. 2018;9(7):1740-52.
44. Sarker SD, Nahar L. Natural medicine: the genus Angelica. *Curr Med Chem*. 2004;11(11):1479-500.
45. Negi AS, Kumar JK, Luqman S, Shanker K, Gupta MM, Khanuja SP. Recent advances in plant hepatoprotectives: a chemical and biological profile of some important leads. *Med Res Rev*. 2008;28(5):746-72.
46. Engels FK, Mathot RA, Verweij J. Alternative drug formulations of docetaxel: a review. *Anticancer Drugs*. 2007;18(2):95-103.
47. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. *Clin Cancer Res*. 2002;8(3):641-61.
48. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. *Nat Chem Biol*. 2009;5(9):616-24.
49. Stockwell BR. Chemical genetics: ligand-based discovery of gene function. *Nat Rev Genet*. 2000;1(2):116-25.
50. Shalem O, Sanjana NE, Zhang F. High-throughput functional genomics using CRISPR-Cas9. *Nat Rev Genet*. 2015;16(5):299-311.